Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients

Launched by NEW VALLEY UNIVERSITY · Jul 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how two medications, dexmedetomidine and ketamine, affect patients who are recovering from severe abdominal infections and have undergone surgery. The main goal is to see how these medications influence the body’s inflammatory response and blood flow stability after surgery. Participants in this study will be patients who are in the Intensive Care Unit (ICU) following specific types of abdominal surgeries, such as those for perforated intestines or bowel blockages.

To be eligible for this trial, participants must be adults who need sedation and help with breathing after their surgery. However, individuals with certain health issues, such as severe heart, kidney, or liver problems, or those who are pregnant, cannot participate. If someone joins the trial, they can expect to receive one of the two medications for their recovery, and researchers will closely monitor how their body responds to treatment. This study aims to improve care for patients who experience serious abdominal conditions, helping doctors understand the best ways to manage their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Adult patients admitted to ICU after ileus surgery (perforated viscus, infarcted bowel, strangulated hernia, anastomotic leakage, diverticulitis, and intestinal obstruction), and who will be expected to require postoperative sedation and ventilation.
• • Abdominal sepsis was determined as organ dysfunction with a substantial change in overall SOFA score (2) ≥ 2 points because of intra-abdominal sepsis.
• Exclusion Criteria:
• • • Known allergy to ketamine, dexmedetomidine,
• • Confirmed pregnancy,
• • Heart failure (class 3 or 4 of the New York Heart Association),
• • Renal failure (RIFLE classification),
• • Liver failure (manifested by serum total protein concentration \<3 g/dl and total bilirubin \>5 mg/dl)
• • Known or suspected brain death.
• • Patients who receive neuromuscular blockers during the first 48 hours of ICU admission will also be excluded.